This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2000 Sep 25;160(17):2683-4.

doi: 10.1001/archinte.160.17.2683.

Underutilization of lipid-lowering therapy in coronary artery disease

A Batalla, S Hevia, J R Reguero, G I Cubero

PMID: 10999994
DOI: 10.1001/archinte.160.17.2683

Comment

Underutilization of lipid-lowering therapy in coronary artery disease

A Batalla et al. Arch Intern Med. 2000.

. 2000 Sep 25;160(17):2683-4.

doi: 10.1001/archinte.160.17.2683.

Authors

A Batalla, S Hevia, J R Reguero, G I Cubero

PMID: 10999994
DOI: 10.1001/archinte.160.17.2683

No abstract available

PubMed Disclaimer

Comment on

Sex bias and underutilization of lipid-lowering therapy in patients with coronary artery disease at academic medical centers in the United States and Canada. Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT) Investigators.
Miller M, Byington R, Hunninghake D, Pitt B, Furberg CD. Miller M, et al. Arch Intern Med. 2000 Feb 14;160(3):343-7. doi: 10.1001/archinte.160.3.343. Arch Intern Med. 2000. PMID: 10668836 Clinical Trial.

Similar articles

[Treatment of high blood cholesterol in patients with coronary heart disease].
Nagai Y, Yamashita S. Nagai Y, et al. Nihon Rinsho. 2003 Apr;61 Suppl 4:675-81. Nihon Rinsho. 2003. PMID: 12735049 Review. Japanese. No abstract available.
Aggressive lipid therapy in the statin era.
Farmer JA. Farmer JA. Prog Cardiovasc Dis. 1998 Sep-Oct;41(2):71-94. doi: 10.1016/s0033-0620(98)80006-6. Prog Cardiovasc Dis. 1998. PMID: 9790411 Review.
Therapeutic efficacy of the lipid-lowering armamentarium: the clinical benefits of aggressive lipid-lowering therapy.
Hunninghake DB. Hunninghake DB. Am J Med. 1998 Feb 23;104(2A):9S-13S. doi: 10.1016/s0002-9343(98)00040-0. Am J Med. 1998. PMID: 9550501 Clinical Trial.
Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
Evans M, Roberts A, Davies S, Rees A. Evans M, et al. Drugs. 2004;64(11):1181-96. doi: 10.2165/00003495-200464110-00003. Drugs. 2004. PMID: 15161326 Review.
Eligibility for lipid-lowering drug therapy in primary prevention: how do the Adult Treatment Panel II and Adult Treatment Panel III Guidelines compare?
Gotto AM Jr, Kuller LH. Gotto AM Jr, et al. Circulation. 2002 Jan 15;105(2):136-9. Circulation. 2002. PMID: 11790688 No abstract available.

See all similar articles

Cited by

Continuity of long-term medication use after surgical hospital stay.
Hach I, Maywald U, Meusel D, König JU, Kirch W. Hach I, et al. Eur J Clin Pharmacol. 2005 Jul;61(5-6):433-8. doi: 10.1007/s00228-005-0934-5. Epub 2005 Jun 10. Eur J Clin Pharmacol. 2005. PMID: 15947922
Prescription patterns of hypolipidaemic drugs in a tertiary care teaching hospital of southern India.
Raja S, Mohapatra S, Kumar JS, Rani RJ. Raja S, et al. J Clin Diagn Res. 2014 Apr;8(4):HC01-3. doi: 10.7860/JCDR/2014/8010.4206. Epub 2014 Apr 15. J Clin Diagn Res. 2014. PMID: 24959461 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Medical
- MedlinePlus Health Information